3Rosenstock J, Schwartz SL, Clark CM Jr, et al, Basa linsulin therapy in type 2 Diabetes: 28 - week comparison of insulin glargine ( HOM901 ) and NPH insulin. Diabetes Care 2001 ;24:631 -636.
8MR Rizzo, M Barbieri, R Grella, N Passariello, M Barone, G Paolisso Diabetes Metab 2004;30:81 -89.
二级参考文献10
1Cryer PE. Hypoglycemia s the limiting factor in the management of diabetes. Diabete Metab Res Rev, 1999, 15 ( 1 ) : 42-46.
2Brink SJ, Miller M, Moltz KC. Education and multidisciplinary- team care concepts for pediatric and adolescent diabetes mellitus. J Pediatr Endocrinol Metab, 2002, 15 (8): 1113-1130.
3Takino T, Yasui H. Yoshitake A, et al. A new halogenated antidiabetic vanadyl complex, bis (5-iodopicolinato) oxovanadium (Ⅳ): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis. J Biol Inorg Chem, 2001 . 6 (2) : 133-142.
5Rosenstock J, Schwartz SL. Clark C, et al. Basal insulin therapy in type 2 diabetes: 27-week comparison of insulin glargine ( HOM901 ) and NPH insulin. Diabetes Care, 2001, 24 ( 11 ) : 631-636.
6Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therap) of type 2 diabetes patients. Diabetes Care. 2003, 26 ( 11 ) : 3080-3086.
7Rossetti P, Pampanelli S, Fanclli C. et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003,26 (5): 1490-1496.
